8 completed, 2 recruiting, 2 terminated, 1 unknown. 13 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Completed 8, Recruiting 2, Terminated 2, Unknown 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow fosaprepitant: new trials by email Literature Review of fosaprepitant trials Research Report on fosaprepitant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen Fosaprepitant, Tropisetron, Olanzapine - Multiple Myeloma | Phase 3 | Recruiting | The Affiliated People's Hospital of Ningbo University | 92 | 2025-10-31 | 2026-02-17 |
| To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy. QLM2010 for injection;dexamethasone, fosaprepitant dimeglumine for injection;palonosetron hydrochloride injection;dexamethasone - Chemotherapy-Induced Nausea and Vomiting | Phase 3 | Completed | Qilu Pharmaceutical Co., Ltd. | 665 | 2025-01-03 | 2025-11-18 |
| Antiemetic Fosaprepitant To Remedy Nausea and Vomiting Fosaprepitant 150 mg, Ondansetron 4 mg - Nausea and Vomiting, Nausea | Phase 2 / Phase 3 | Recruiting | Montefiore Medical Center | 200 | 2024-11-13 | 2026-05-18 |
| Clinical Study of HR20013 for Injection in Patients With Malignant Solid Tumors HR20013 for injection;dexamethasone, fosaprepitant dimeglumine for injection;palonosetron hydrochloride injection;dexamethasone - Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy | Phase 3 | Completed | Fujian Shengdi Pharmaceutical Co., Ltd. | 754 | 2022-09-21 | 2023-10-27 |
| Anti-emetic Prophylaxis With or Without Dexamethasone Fosaprepitant, tropisetron, and olanzapine-based antiemetic regimen, Fosaprepitant, tropisetron, olanzapine, and dexamethasone-based antiemetic regimen - Chemotherapy-induced Nausea and Vomiting | Phase 3 | Completed | Henan Cancer Hospital | 442 | 2022-02-01 | 2024-10-10 |
| Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer Fosaprepitant, tropisetron, Dexamethasone - Cervical Cancer, Nasopharyngeal Cancer | Phase 3 | Completed | Shantou University Medical College | 116 | 2021-07-01 | 2024-02-06 |
| Granisetron Transdermal Patch for Prophylaxis of Delayed CINV Granisetron transdermal patch, Palonosetron, Aprepitant - Chemotherapy-induced Nausea and Vomiting (CINV) | Phase 3 | Unknown | Fudan University | 140 | 2021-06-10 | 2021-06-03 |
| Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients Ondansetron, Dexamethasone, Neurokinin-1 Receptor Antagonist (NK1-RA) - Gynecologic Cancer | Phase 3 | Terminated | University of Michigan Rogel Cancer Center | 62 | 2020-12-28 | 2025-06-18 |
| Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy Palonosetron Hydrochloride, Ondansetron Hydrochloride, Dexamethasone - Malignant Neoplasm | Phase 3 | Completed | Alliance for Clinical Trials in Oncology | 690 | 2018-11-20 | 2025-04-06 |
| Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044) Fosaprepitant, Placebo for fosaprepitant, Ondansetron - Chemotherapy-induced Nausea and Vomiting | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 75 | 2015-09-14 | 2019-03-15 |
| A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC APF530, Ondansetron, Ondansetron placebo - Chemotherapy-induced Nausea and Vomiting | Phase 3 | Completed | Heron Therapeutics | 942 | 2014-03-01 | 2026-03-02 |
| Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031) Fosaprepitant dimeglumine, Fosaprepitant Placebo, Dexamethasone - Chemotherapy-Induced Nausea and Vomiting (CINV) | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1015 | 2012-09-24 | 2018-09-04 |
| Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin Fosaprepitant dimeglumine, Placebo - Nausea, Vomiting | Phase 3 | Completed | Odense University Hospital | 246 | 2010-04-01 | 2015-04-24 |
Vomiting (9) · Nausea (3) · Genital Neoplasms, Female (1) · Multiple Myeloma (1) · Nasopharyngeal Neoplasms (1) · Neoplasms (1) · Signs and Symptoms, Digestive (1) · Uterine Cervical Neoplasms (1)
Merck Sharp & Dohme LLC (2) · Alliance for Clinical Trials in Oncology (1) · Fudan University (1) · Fujian Shengdi Pharmaceutical Co., Ltd. (1) · Henan Cancer Hospital (1) · Heron Therapeutics (1) · Montefiore Medical Center (1) · Odense University Hospital (1) · Qilu Pharmaceutical Co., Ltd. (1) · Shantou University Medical College (1) · The Affiliated People's Hospital of Ningbo University (1) · University of Michigan Rogel Cancer Center (1)
China (5) · United States (4) · Australia (1) · Denmark (1) · Germany (1) · Guam (1) · Norway (1)
Aimee Rolston (1) · Benjamin W Friedman, MD MS (1) · Christina Ruhlmann, MD (1) · Chuangzhen Chen (1) · Dorothy Keefe, MD, FRACP (1) · Felix Hilpert, MD, DMSci (1) · Gunnar Kristensen, MD, PhD (1) · Henrik Roed, MD, DMSci (1) · Jacob C Lindegaard, MD (1) · Jorn Herrstedt, MD, DMSci (1) · Mark Gelder, MD (1) · Peipei Ye (1) · Petra Feyer, MD, DMSci (1) · Rudolph Navari, MD, PhD, FACP (1)
PMID 26449391, PMID 26952945, PMID 26997579, PMID 29808377, PMID 32988373, PMID 37284847, PMID 37851143, PMID 39621965, PMID 41520166
2009 (1), 2014 (1), UG1CA189823 (1)